AS PART OF PATIENT ADVOCACY, SAVE YOUR SKIN FOUNDATION IS ONE OF THE SELECT PATIENT ADVOCACY ORGANIZATIONS THAT IS APPROVED TO SUBMIT TREATMENT RECOMMENDATIONS TO THE CADTH COMMON DRUG REVIEW (CDR), TO PCODR (PAN-CANADIAN ONCOLOGY DRUG REVIEW) AND INESSS (INSTITUT NATIONAL D’EXCELLENCE EN SANTÉ ET EN SERVICES SOCIAUX) FROM THE PATIENT PERSPECTIVE. CLICK HERE TO LEARN MORE ABOUT CADTH AND INESSS
Thank you to all patients and their caregivers who share their experience and feedback in our anonymous online surveys regarding treatments they have had – this feedback goes directly to decision-makers in the drug approval process across Canada. Watch our social media channels for updates on current recommendations and approvals.
Basal Cell Carcinoma
Save Your Skin Foundation is pleased to announce that Health Canada has approved Libtayo® (cemiplimab) for patients with locally advanced basal cell carcinoma (LaBCC), previously treated with a hedgehog pathway inhibitor (HHI).
November 5, 2021 – Click here to read the press release
Health Canada has approved BRAFTOVI (encorafenib) to be used in combination with MEKTOVI (binimetinib), for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation..
March 30, 2021 – Click here to read the press release
We hope that every province and territory will take swift steps to list this drug on their public formularies in order to make this therapy available to patients.
Save Your Skin Foundation is pleased to have submitted patient feedback on the targeted therapy Braftovi™ in combination with Mektovi®, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. SYSF also supported Health Care Providers with their Clinician Input submissions for this treatment.
Stay updated on the CADTH website HERE
Squamous Cell Carcinoma
Save Your Skin Foundation Applauds the pan-Canadian Oncology Drug Review recommendation for Provincial Reimbursement of Libtayo™ for the treatment of Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
January 15, 2020 – Click here to read the press release
Melanoma – stage III
SYSF is delighted to see pCODR issue its final recommendation for Keytruda® (pembrolizumab) for Canadian patients with melanoma in the adjuvant setting.
And we applaud pCODR for issuing its final recommendation for Opdivo® (nivolumab) for Canadian patients with melanoma in the adjuvant setting.
Making awareness and education available is crucial. Since 2006, the Foundation has worked to raise awareness of melanoma and non-melanoma skin cancers focusing on education, prevention and the need for improved patient care.